Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Cinti, Caterina ^a   Taranta, Monia ^a   Naldi, Ilaria ^a   Grimaldi, Settimio ^b  

^a CNR   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; MAGNETIC NANOPARTICLE; VIROSOME; VIRUS SPIKE PROTEIN; ANTINEOPLASTIC AGENT; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; MAGNETITE NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOMEDICAL ENGINEERING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOFABRICATION; NONHUMAN; SUSTAINED RELEASE PREPARATION; TANDEM MASS SPECTROMETRY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CHEMISTRY; CHICK EMBRYO; DRUG DELIVERY SYSTEM; ERYTHROCYTE TRANSFUSION; EVALUATION; GROWTH, DEVELOPMENT AND AGING; HELA CELL; ISOLATION AND PURIFICATION; MAGNETISM; METABOLISM; METHODOLOGY; ONCOLYTIC VIROTHERAPY; ORTHOMYXOVIRUS; PHYSIOLOGY; TISSUE ENGINEERING; UTILIZATION REVIEW; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHICK EMBRYO; DRUG DELIVERY SYSTEMS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HELA CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; MAGNETICS; MAGNETITE NANOPARTICLES; ONCOLYTIC VIROTHERAPY; ORTHOMYXOVIRIDAE; TISSUE ENGINEERING; VIROSOMES;

EID: 79952025755     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017132     Document Type: Article

References (44)

1. Allen TM, Cullis PR, (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822.
2. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM, (2004) Recent advances on chitosan-based micro and nanoparticles in drug delivery. J Control Release 100: 5-28.
3. Aminabhavi TM, Soppimath KS, Kulkarni AR, Rudzinski WE, (2001) Biodegradabile polymeric nanoparticles as drug delivery devices. J Control Release 70: 1-20.
4. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, et al. (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 108: 193-214.
5. Liu M, Kono K, Fréchet JM, (2000) Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release 65 (1-2): 121-131.
6. Moghimi SM, Hunter AC, (2001) Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 18 (6): 527-550.
7. Moghimi SM, Hunter AC, Murray JC, (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53 (2): 283-318.
8. Carrasquillo KG, Stanley AN, Aponte-Carro JC, De Jésus P, Costantino HR, et al. (2001) Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-coglycolide) microspheres results in release of native protein. J Control Release 76: 199-208.
9. Ravi Kumar MNV, Bakowsky U, Lehr CM, (2004) Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials pp. 25, 1771-1777.
10. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM, (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125: 193-209.
11. Bittner B, Ronneberger B, Zange R, Volland C, Anderson JM, et al. (1998) Bovine serum albumin loaded poly(lactide-co-glycolide) microspheres: the influence of polymer purity on particle characteristics. J Microencapsul 15: 495-514.
12. Johansen P, Men Y, Audran R, Corradin G, Merkle HP, et al. (1998) Improving stability&release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 15: 1103-1110.
13. Pierigè F, Serafini S, Rossi L, Magnani M, (2008) Cell-based drug delivery. Adv Drug Deliv Rev 60: 286-295.
14. Cestmir A, (2008) Prodrug cancer gene therapy. Cancer letter 270: 191-201.
15. Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, et al. (2006) Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery J Leukoc Biol 80 (5): 1165-1174.
16. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, et al. (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
17. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, et al. (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608.
18. Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S, (2007) Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control. Relase 118: 145-160.
19. Rossi L, Serafini S, Pierigé F, Antonelli A, Cerasi A, et al. (2005) Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2 (2): 311-322.
20. Provotorov VM, Ivanova GA, (2009) The role of erythrocytes in the system of controlled transport of pharmaceutical agents. Klin Med 87: 4-8.
21. Zimmermann U, (1983) Cellular drug-carrier systems and their possible targeting. In: Goldberg EP, editors. pp. 153-200 Targeted Drugs, Wiley, New York,.
22. Sprandel U, (1987) Towards cellular drug targeting and controlled release of drugs by magnetic fields. Adv Biosci 67: 243-250.
23. Sprandel U, Lanz DJ, Horsten WV, (1987) Magnetically responsive erythrocyte ghosts. Methods Enzymol 149: 301-312.
24. Mayer CR, Geis NA, Katus HA, Bekeredjian R, (2008) Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin Drug Deliv 5 (10): 1121-1138.
25. Price RJ, Skyba DM, Kaul S, Skalak TC, (1998) Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 98 (13): 1264-1267.
26. Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, et al. (2009) Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 22: 1194-1204.
27. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, et al. (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20 (7): 1117-1126.
28. Patel K, Guichard SM, Jodrell D, (2008) Simultaneous determination of decitabine and vorinostat (suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry fro clinical studies. J Chromatography B 863: 19-25.
29. Hamidi M, Tajerzadeh H, (2003) Carrier erythrocytes: an overview. Drg.Del 10 (1): 9-20.
30. Gutiérrez Millán C, Zarzuelo Castañeda A, Sayalero Marinero ML, Lanao JM, (2004) Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol Dis 33 (2): 132-140.
31. Gutiérrez Millán C, Zarzuelo Castañeda A, González López F, Sayalero Marinero ML, Lanao JM, (2008) Pharmacokinetics and biodistribution of amikacin encapsulated in carrier erythrocytes. J Antimicrob Chemother 61 (2): 375-381.
32. Gutiérrez Millán C, Bax BE, Castañeda AZ, Marinero ML, Lanao JM, (2008) In vitro studies of amikacin-loaded human carrier erythrocytes. Transl Res 152 (2): 59-66.
33. Orekhova NM, Akchurin RS, Belyaev AA, Smirnov MD, Ragimov SE, et al. (1990) Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. Thromb Res 57 (4): 611-616.
34. Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, et al. (2002) Erythrocyte- mediated delivery of drugs, peptides and modified oligonucleotides. Gene therapy 9: 749-751.
35. Momparler RL, (2005) Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 42: S9-S16.
36. Leone G, Teofili L, Voso MT, Lubbert M, (2002) DNA methylation and demethylating drugs in myelodysplastic syndormes and secondary leukemias. Haematologica 32: 1324-1341.
37. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (8): 1794-1803.
38. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, et al. (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12 (19): 5777-5785.
39. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, et al. (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25 (29): 4603-4609.
40. Christman JK, (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21 (35): 5483-5495.
41. Jüttermann R, Li E, Jaenisch R, (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91 (25): 11797-11801.
42. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R, (1997) Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A 94 (9): 4681-4685.
43. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, et al. (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20 (7): 1117-1126.
44. Wallace SS, (2002) Biological consequences of free radical-damaged DNA bases. Free Radic Biol Med 33 (1): 1-14.